查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1863071

按產品類型、藥物類別、給藥途徑、病患類型、治療用途和分銷管道學名藥市場－2025年至2032年全球預測

Generic Drugs Market by Product Type, Drug Class, Route of Administration, Patient Type, Therapeutic Application, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，學名藥市場規模將成長至 8,513.6 億美元，年複合成長率為 9.38%。

關鍵市場統計數據
基準年 2024 4152.8億美元
預計年份：2025年 4522.8億美元
預測年份 2032 8513.6億美元
複合年成長率 (%) 9.38%

學名藥產業策略架構：明確可負擔性、監管嚴格性和供應鏈韌性之間的關係

學名藥產業已發展成為全球現代醫療保健體系的基石，在確保藥品價格可負擔性的同時，也兼顧了品質和供應永續性等關鍵要素。近年來，隨著監管審查力度加大、生產和分銷環節的技術快速應用以及對供應鏈透明度的日益重視，生產商、經銷商和支付方都積極應對了不斷變化的市場環境。這些趨勢正在重新定義競爭格局，並影響相關人員對產能、合規性和能力建構等方面的投資優先順序。

同時，相關人員的期望也在不斷提高。監管機構要求更嚴格的品管和上市後監管，支付方對定價和處方集趨勢施加壓力，醫療服務提供者要求基本藥物供應的可靠性和持續性，而患者和權益倡導團體則越來越期望能夠公平地獲得有效的治療。因此，那些將卓越營運、適應性監管策略和強大的合作夥伴生態系統結合的公司，正在成為更具韌性的市場參與者。

本導言為深入探討轉型轉變、關稅的影響、細分市場洞察、區域細微差別、企業策略、實用建議和嚴謹的調查方法奠定了基礎，旨在為經營團隊和投資者提供對該行業結構促進因素和近期優先事項的連貫理解，並支持在商業、營運和監管領域做出切實可行的決策。

技術創新、不斷演變的分銷模式和日益嚴格的監管如何重新定義全球學名藥生態系統中的競爭優勢

學名藥產業格局正在經歷一場變革，這場變革正在重塑其競爭力和價值創造模式。在生產製造方面，連續生產流程、模組化設施和數位雙胞胎技術的進步正在提高生產效率並降低批次間差異，從而實現更快的規模化生產和更穩定的品質結果。同時，分析品管和即時上市前檢測正逐漸成為標準要求而非差異化優勢，迫使企業在產品生命週期規劃的早期階段就融入這些能力。

除了製造業之外，商業結構也在改變。線上藥局和直接面向患者的配送管道的興起，對傳統的經銷網路構成了挑戰，並透過整合物流解決方案和患者依從性服務創造了新的盈利機會。同時，批發商和醫院採購部門正在整合採購流程，策略性合約和差異化服務的重要性日益凸顯。

監管和政策的變化也產生了顯著影響。監管機構正在修訂核准流程以適應學名藥的複雜性，並加強核准後監測要求，這影響了生命週期管理的成本和時間。此外，對供應鏈採購路徑和原料採購的審查力道加大，促使企業投資鄰近地區以降低集中風險。這些變化共同推動了產品組合的合理化、策略聯盟的建立以及對能夠維持長期競爭力的技術平台的定向投資。

對2025年關稅變化如何重塑學名藥供應鏈的籌資策略、供應鏈韌性和政策應對措施進行實證評估

2025年貿易政策和關稅結構的調整為學名藥生產商及其供應鏈合作夥伴帶來了新的營運和策略考量。某些活性藥物原料藥（API）、輔料和包裝材料的關稅提高，導致依賴現有採購區域的公司進口原料成本上升。這促使企業加速對供應商組合和原料策略進行重新評估，以平衡短期成本壓力與長期可靠性和合規性。

重點，關稅的連鎖反應遠不止於直接投入成本。它會影響與經銷商和付款方的合約談判，改變長期供應協議的經濟效益，並提升垂直整合製造能力的價值。為此，一些企業正透過擴大國內戰略製造能力或建立安全的多源採購框架來尋求更高程度的整合，而另一些企業則專注於提高免稅地區替代供應商的資質，或重新設計配方以減少對受限原料的依賴。

從監管和政策角度來看，不斷變化的關稅環境促進了行業團體和政策制定者之間的對話，旨在為基本藥物和關鍵供應鏈材料製定有針對性的關稅豁免政策。這些努力體現了人們認知到，持續供應基本藥物是公共衛生領域的優先事項。摘要，2025年的關稅調整推動了務實的供應策略重組，刺激了對供應冗餘和合規性採購的投資，並重申了積極參與政策制定以保障民眾獲得可負擔藥物的重要性。

詳細的細分分析揭示了產品類型、藥物類別、給藥途徑、患者群體、治療用途和分銷管道如何影響策略重點。

細分市場分析揭示了不同產品類型、藥物類別、給藥途徑、患者群體、治療用途和分銷管道的需求差異、監管要求和商業性策略。基於產品類型，非處方仿製學名藥和處方仿製學名藥的市場動態存在差異：非處方藥高度依賴消費者品牌、快速補貨和零售貨架最佳化，而處方箋學名藥受處方醫生接受度、支付方合約和醫保目錄收錄的影響。依藥物類別分類，抗憂鬱劑、抗生素、處方箋藥、抗糖尿病藥、抗組織胺藥物和抗高血壓藥等類別各自具有獨特的監管考慮、需求彈性以及臨床替代模式，這些都會影響產品系列的優先排序。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 在主要市場中，專利到期生物相似藥抗癌藥物的採用率不斷提高
  • 來自國家醫療保健系統的戰略定價壓力加速了專利到期藥品的成本降低。
  • 用於吸入和經皮給藥系統的複雜學名藥的核准正在迅速擴大。
  • 將人工智慧融入學名藥製劑開發和生產流程
  • 透過擴大學名藥生產商和合約研究組織（CDMO）之間的合作來最佳化生產能力
  • 為簡化多個新興市場學名藥的核准流程，監管協調工作正在進行中。
  • 為使發展中國家能夠獲得低成本的非專利抗病毒藥物，強制許可談判激增
  • 提高學名藥生產商之間的垂直整合程度，以減少原料藥供應鏈中斷。
  • 學名藥和數位療法在慢性病管理中的出現
  • 遠端保健的普及加速了消費者偏好向非專利家用診斷試劑套件的轉變

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 按產品類型學名藥市場

  • 非處方（OTC）學名藥
  • 處方箋學名藥

第9章 按藥物類別學名藥市場

  • 止痛藥
  • 抗生素
  • 抗憂鬱症
  • 抗糖尿病藥物
  • 抗組織胺藥
  • 抗高血壓藥物

第10章 依給藥途徑分類的學名藥市場

  • 吸入劑
  • 注射
  • 口服
  • 外用藥物

第11章 按病患類型分類的學名藥市場

  • 成人版
  • 老年人
  • 孩子們

第12章 按治療應用分類的學名藥市場

  • 抗感染藥物
  • 循環系統
  • 中樞神經系統（CNS）
  • 糖尿病
  • 腫瘤學
  • 呼吸系統

第13章 按通路分類的學名藥市場

  • 離線
    • 醫院藥房
    • 零售藥房
  • 網路藥房

第14章 各地區學名藥市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 按類別分類的學名藥市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 各國學名藥市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Pfizer, Inc.
    • Sanofi SA
    • Abbott Laboratories
    • Alembic Pharmaceuticals Limited
    • Alkem Laboratories Limited
    • Amneal Pharmaceuticals, Inc.
    • Aspen Pharmacare Holdings Limited
    • Aurobindo Pharma Limited
    • Bausch Health Companies Inc.
    • Baxter International Inc.
    • Biocon Limited
    • Cipla Limited
    • Dr. Reddy's Laboratories Ltd.
    • Eli Lilly and Company
    • Endo, Inc.
    • Fresenius SE & Co. KGaA
    • GlaxoSmithKline PLC
    • Glenmark Pharmaceuticals Limited
    • Hikma Pharmaceuticals PLC.
    • Intas Pharmaceuticals Ltd.
    • Krka, dd
    • Lupin Limited
    • Sandoz Group AG
    • STADA Arzneimittel AG
    • Sun Pharmaceutical Industries Limited
    • Teva Pharmaceutical Industries Ltd.
    • Viatris Inc.
    • Zydus Lifesciences Limited
Product Code: MRR-F6513A06BE93

The Generic Drugs Market is projected to grow by USD 851.36 billion at a CAGR of 9.38% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 415.28 billion
Estimated Year [2025] USD 452.28 billion
Forecast Year [2032] USD 851.36 billion
CAGR (%) 9.38%

A strategic framing of the generic pharmaceutical sector that clarifies the intersection of affordability, regulatory intensity, and supply chain resilience

The generic drugs sector has evolved into a cornerstone of modern healthcare systems worldwide, balancing affordability with the imperative for quality and supply resilience. In recent years, manufacturers, distributors, and payers have navigated a shifting environment characterized by intensifying regulatory scrutiny, rapid technological adoption in manufacturing and distribution, and an increased emphasis on supply chain transparency. These dynamics are redefining competitive positioning, and they are shaping how stakeholders prioritize investments in capacity, compliance, and capability.

At the same time, stakeholder expectations continue to broaden. Regulators demand more rigorous quality controls and post-market surveillance, payers pressure price and formulary dynamics, and healthcare providers seek reliable supply continuity for essential therapies. Meanwhile, patients and advocacy groups increasingly expect equitable access to effective treatments. Consequently, companies that combine operational excellence with adaptive regulatory strategies and strong partner ecosystems are emerging as more resilient players.

This introduction sets the stage for a detailed examination of transformative shifts, tariff impacts, segmentation insights, regional nuances, company strategies, actionable recommendations, and methodological rigor. It aims to equip executives and investors with a coherent understanding of the sector's structural drivers and near-term priorities, supporting pragmatic decision-making across commercial, operational, and regulatory domains.

How technological innovation, evolving distribution models, and regulatory rigor are redefining competitive advantage across the global generics ecosystem

The landscape for generic pharmaceuticals is in the midst of transformative shifts that are altering competitive dynamics and value creation models. In manufacturing, advances in continuous processing, modular facilities, and digital twins are improving throughput and reducing batch variability, enabling faster scale-up and more consistent quality outcomes. Parallel to this, analytics-driven quality control and real-time release testing are becoming standard expectations rather than differentiators, which is compelling firms to embed these capabilities early in product lifecycle planning.

Beyond manufacturing, the commercial architecture is changing. The growth of online pharmacies and direct-to-patient fulfillment channels is challenging traditional distribution networks, creating opportunities to capture margin through integrated logistics solutions and patient adherence services. Simultaneously, wholesalers and hospital procurement groups are consolidating purchasing practices, which increases the importance of strategic contracting and differentiated service offerings.

Regulatory and policy shifts are exerting significant influence as well. Regulators are revising approval pathways to address complex generics and are increasing post-approval surveillance requirements, which affects the cost and time for lifecycle management. Moreover, heightened scrutiny on supply chain provenance and raw material sourcing is prompting near-shore investment as firms seek to mitigate concentration risks. Taken together, these shifts are prompting portfolio rationalization, strategic partnerships, and targeted investments in technology platforms that can sustain long-term competitiveness.

An evidence-based assessment of how 2025 tariff shifts are reshaping sourcing strategies, supply resilience, and policy engagement across the generic drug supply chain

The reconfiguration of trade policy and tariff structures in 2025 has introduced a new set of operational and strategic considerations for generic drug manufacturers and their supply chain partners. Increased duties on certain active pharmaceutical ingredients (APIs), excipients, and packaging materials have elevated the cost of imported inputs for companies that rely on established sourcing geographies. This has, in turn, accelerated strategic reassessment of supplier portfolios and raw material strategies, with firms balancing near-term cost pressures against longer-term reliability and compliance.

Importantly, the tariffs' ripple effects extend beyond direct input costs. They influence contract negotiations with distributors and payers, alter the economics of long-term supplier agreements, and increase the value of vertically integrated manufacturing capabilities. In response, some organizations have pursued greater integration, either through strategic domestic capacity expansion or by establishing secured, multi-source procurement frameworks. Meanwhile, others have intensified efforts to qualify alternative suppliers in tariff-exempt jurisdictions or to redesign formulations that reduce dependence on constrained inputs.

From a regulatory and policy perspective, the tariff landscape has also prompted dialogues between industry consortia and policymakers aimed at creating targeted exemptions for essential medicines and critical supply chain inputs. These engagements reflect a recognition that supply continuity for essential therapies is a public health priority. In summary, the 2025 tariff adjustments have catalyzed a pragmatic reshaping of supply strategies, stimulated investment in supply redundancy and compliance-driven sourcing, and reinforced the importance of proactive policy engagement to safeguard access to affordable medicines.

Granular segmentation insights that reveal how product type, drug class, administration route, patient cohorts, therapeutic application, and distribution channels shape strategic priorities

Segmentation lenses reveal differentiated drivers of demand, regulatory requirements, and commercial approaches across product types, drug classes, routes of administration, patient cohorts, therapeutic applications, and distribution channels. Based on product type, the market dynamics diverge between Over-the-Counter (OTC) Generic Drugs and Prescription Generic Drugs: OTC offerings rely heavily on consumer-facing branding, rapid replenishment and retail shelf optimization, whereas prescription generics are shaped by prescriber acceptance, payer contracting, and formulary placement. Based on drug class, categories such as Analgesics, Antibiotics, Antidepressants, Antidiabetics, Antihistamines, and Antihypertensives each present unique regulatory considerations, demand elasticity, and clinical substitution patterns that influence portfolio prioritization.

Based on route of administration, distinctions among Inhalations, Injectables, Oral, and Topical forms are pronounced; for instance, injectables often require specialized manufacturing and cold-chain logistics, inhalation products face device compatibility and regulatory device-drug interface scrutiny, while oral and topical formulations emphasize scalable, cost-efficient production and stability. Based on patient type, markets for Adult, Geriatric, and Pediatric patients differ in dosing complexity, safety monitoring, and formulation preferences, driving distinct R&D and labeling priorities. Based on therapeutic application, Anti-infectives, Cardiovascular, Central Nervous System (CNS), Diabetes, Oncology, and Respiratory segments each demand tailored lifecycle management, with oncology and CNS often involving higher complexity generics or specialty delivery considerations. Lastly, based on distribution channel, the dual pathways of Offline and Online Pharmacies require distinct strategies: Offline encompasses Hospital Pharmacies and Retail Pharmacies with institutional contracting and point-of-care stocking imperatives, while Online channels emphasize fulfillment speed, digital adherence tools, and omnichannel patient engagement.

Integrating these segmentation perspectives enables more granular strategy design. For example, a prescription antihypertensive targeted at geriatric patients will require a different commercialization, reimbursement, and risk-management plan than an OTC analgesic aimed at broad adult consumers. Recognizing these nuanced segmentation interactions helps leaders allocate resources to the combinations that present the most sustainable clinical and commercial advantage.

Region-specific strategic implications that clarify how the Americas, Europe Middle East & Africa, and Asia-Pacific each drive distinct regulatory, manufacturing, and access considerations

Regional dynamics continue to exert a first-order influence on competitive strategy, regulatory engagement, and supply chain design across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, payer-driven reforms, a high level of biosimilar adoption in some therapeutic areas, and a mature retail pharmacy infrastructure create an environment where contract negotiation sophistication and supply reliability are strategic differentiators. Meanwhile, public procurement mechanisms and policy levers frequently shape availability and pricing decisions, requiring close alignment with national reimbursement frameworks.

In Europe, Middle East & Africa, regulatory harmonization efforts coexist with varied national reimbursement systems and regional manufacturing strengths. European markets often emphasize rigorous quality and pharmacovigilance standards, while some Middle East and African jurisdictions are focused on improving supply chain infrastructure and local manufacturing capacity. As a result, companies frequently adopt differentiated regulatory strategies across the region, using centralized pathways where possible and country-level adaptations where necessary.

Asia-Pacific presents a highly heterogeneous tapestry, combining advanced regulatory systems and large domestic manufacturers with rapidly evolving demand patterns in emerging markets. The region's prominence in API production and contract manufacturing makes it a critical node in global supply chains, yet rising labor costs and policy incentives for domestic production are prompting strategic recalibrations. Across these regions, successful organizations adapt commercial models, forge local partnerships, and tailor supply chain configurations to regional policy priorities and healthcare delivery models, thereby achieving both operational efficiency and market access.

Critical company-level priorities and capability investments that determine who will sustain competitive advantage through quality, integration, and strategic partnerships

Key company strategies in the generics domain increasingly converge on a set of capabilities that drive resilience and competitive differentiation. Leading manufacturers prioritize manufacturing excellence, evidenced by investments in quality-by-design, process automation, and digital manufacturing controls that reduce variability and improve regulatory readiness. Contract development and manufacturing organizations (CDMOs) are similarly elevating their role, offering flexible capacity and specialized expertise for complex dosage forms and sterile injectables, which in turn shapes partner selection for brand and generic firms alike.

Strategic portfolio management has also become a central focus. Companies are rationalizing pipelines to concentrate on high-value, technically differentiated generics and niche therapeutic areas where barriers to entry are meaningful. At the same time, some players pursue scale through targeted acquisitions and alliances to secure supply of critical APIs and to broaden geographic reach. Commercially, there is a clear pivot toward integrated service offerings that combine product supply with patient support programs, adherence tools, and digital engagement platforms, enhancing value propositions to payers and providers.

Operationally, firms that excel combine robust regulatory affairs teams with agile supply chain functions capable of multi-source procurement and rapid qualification of alternative suppliers. Collaboration between R&D, regulatory, and commercial functions is essential for accelerating time-to-market for complex generics while maintaining compliance. Collectively, these company-level insights underscore that capability depth in manufacturing, regulatory navigation, and channel integration are the primary levers for sustainable performance.

Immediate and pragmatic strategic actions for leaders to strengthen resilience, accelerate capability building, and capture opportunities across complex generics markets

Industry leaders must adopt a proactive and multi-dimensional strategy to capitalize on structural shifts while mitigating risk. First, strengthening supply chain resilience through supplier diversification and dual-sourcing strategies can reduce exposure to concentrated input markets and trade-policy volatility. This should be accompanied by an accelerated qualification program for alternative suppliers and geographic diversification of contract manufacturing partners to ensure continuity of supply for essential therapies. Second, investing in advanced manufacturing capabilities-such as continuous processing, real-time analytics, and automation-not only lowers variability and production costs but also provides a strategic buffer against regulatory scrutiny.

Third, firms should deepen engagement with payers, providers, and procurement entities to align product value propositions with formulary and reimbursement priorities. Tailored health economic evidence and patient support programs can enhance adoption in competitive therapeutic classes. Fourth, digital-first distribution strategies that integrate online pharmacy channels, adherence platforms, and data-driven customer insights will be critical for capturing shifting consumer behavior and optimizing fulfillment economics. Fifth, prioritize regulatory intelligence and policy advocacy to influence pragmatic exemptions or clarifications where public health imperatives intersect with trade and tariff policies.

Finally, leaders should consider strategic collaborations-ranging from shared API procurement consortia to co-investment in regional manufacturing hubs-to spread capital intensity and speed capability development. By combining these approaches, companies can create a more robust and flexible operating model that sustains access, preserves margins, and supports long-term growth in a fast-evolving environment.

A rigorous mixed-methods research approach combining executive interviews, regulatory review, and cross-source triangulation to ground actionable sector insights

The research supporting these insights employs a structured, mixed-methods approach that combines qualitative and quantitative techniques to ensure robustness and practical relevance. Primary research components include in-depth interviews with executives across manufacturing, distribution, regulatory affairs, and procurement, as well as consultations with clinicians and policy advisors to capture operational realities and emergent clinical priorities. Secondary research involved systematic review of regulatory guidance, industry white papers, company filings, and public trade data to construct a comprehensive view of structural trends and policy developments.

Data synthesis relied on triangulation across sources to validate thematic findings and to surface actionable implications. Where appropriate, case studies and comparative analyses were used to illustrate how specific strategies translated into operational outcomes, focusing on areas such as supply chain realignment, regulatory approvals for complex generics, and commercial channel transformation. The methodology also incorporated sensitivity checks to identify variables most likely to influence strategic outcomes, such as input concentration risk and regulatory pathway complexity.

Limitations are acknowledged: proprietary contract details and confidential pricing arrangements are typically not publicly accessible, and rapidly evolving policy decisions can shift strategic calculus in short windows. To mitigate these constraints, the approach emphasizes scenario-based analysis and stakeholder validation to ensure that recommendations remain practical and timely for executive decision-making.

A succinct synthesis of strategic priorities that highlights resilience, capability investment, and collaborative approaches as keys to enduring success

In conclusion, the generics sector stands at an inflection point where operational excellence, supply chain agility, regulatory foresight, and commercial innovation determine long-term outcomes. The interplay of technological advances in manufacturing, evolving distribution channels, and policy-induced trade dynamics requires companies to recalibrate both near-term tactics and medium-term investments. Firms that proactively diversify sourcing, invest in advanced manufacturing, and align commercial value propositions with payer and provider needs will be better positioned to deliver consistent access and preserve margins.

Moreover, cross-sector collaboration and targeted public-private engagement will be essential to manage systemic risks and to sustain availability of essential medicines. As stakeholders navigate these complexities, a disciplined approach that blends capability investment, partnership strategies, and regulatory engagement will provide a roadmap for resilience. The insights presented here are intended to support leaders in prioritizing actions that yield immediate risk reduction while creating structural advantage over time.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Increased uptake of biosimilar oncology drugs following patent expirations in key markets
  • 5.2. Strategic pricing pressures from national health systems accelerating off-patent drug cost reductions
  • 5.3. Rapid expansion of complex generic approvals for inhalation and transdermal drug delivery systems
  • 5.4. Integration of artificial intelligence in generic drug formulation development and manufacturing processes
  • 5.5. Growing partnerships between generic manufacturers and contract development organizations to optimize capacity
  • 5.6. Regulatory harmonization efforts streamlining generic drug approval across multiple emerging markets
  • 5.7. Surge in compulsory licensing negotiations enabling low-cost generic antivirals in developing nations
  • 5.8. Increasing vertical consolidation among generic drug producers to mitigate API supply chain disruptions
  • 5.9. Emergence of digital therapeutics combined with generic medications for chronic disease management
  • 5.10. Consumer preference shift towards at-home generic diagnostic test kits accelerated by telehealth adoption

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Generic Drugs Market, by Product Type

  • 8.1. Over-the-Counter (OTC) Generic Drugs
  • 8.2. Prescription Generic Drugs

9. Generic Drugs Market, by Drug Class

  • 9.1. Analgesics
  • 9.2. Antibiotics
  • 9.3. Antidepressants
  • 9.4. Antidiabetics
  • 9.5. Antihistamines
  • 9.6. Antihypertensives

10. Generic Drugs Market, by Route of Administration

  • 10.1. Inhalations
  • 10.2. Injectables
  • 10.3. Oral
  • 10.4. Topical

11. Generic Drugs Market, by Patient Type

  • 11.1. Adult
  • 11.2. Geriatric
  • 11.3. Pediatric

12. Generic Drugs Market, by Therapeutic Application

  • 12.1. Anti-infectives
  • 12.2. Cardiovascular
  • 12.3. Central Nervous System (CNS)
  • 12.4. Diabetes
  • 12.5. Oncology
  • 12.6. Respiratory

13. Generic Drugs Market, by Distribution Channel

  • 13.1. Offline
    • 13.1.1. Hospital Pharmacies
    • 13.1.2. Retail Pharmacies
  • 13.2. Online Pharmacies

14. Generic Drugs Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Generic Drugs Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Generic Drugs Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Pfizer, Inc.
    • 17.3.2. Sanofi SA
    • 17.3.3. Abbott Laboratories
    • 17.3.4. Alembic Pharmaceuticals Limited
    • 17.3.5. Alkem Laboratories Limited
    • 17.3.6. Amneal Pharmaceuticals, Inc.
    • 17.3.7. Aspen Pharmacare Holdings Limited
    • 17.3.8. Aurobindo Pharma Limited
    • 17.3.9. Bausch Health Companies Inc.
    • 17.3.10. Baxter International Inc.
    • 17.3.11. Biocon Limited
    • 17.3.12. Cipla Limited
    • 17.3.13. Dr. Reddy's Laboratories Ltd.
    • 17.3.14. Eli Lilly and Company
    • 17.3.15. Endo, Inc.
    • 17.3.16. Fresenius SE & Co. KGaA
    • 17.3.17. GlaxoSmithKline PLC
    • 17.3.18. Glenmark Pharmaceuticals Limited
    • 17.3.19. Hikma Pharmaceuticals PLC.
    • 17.3.20. Intas Pharmaceuticals Ltd.
    • 17.3.21. Krka, d. d.
    • 17.3.22. Lupin Limited
    • 17.3.23. Sandoz Group AG
    • 17.3.24. STADA Arzneimittel AG
    • 17.3.25. Sun Pharmaceutical Industries Limited
    • 17.3.26. Teva Pharmaceutical Industries Ltd.
    • 17.3.27. Viatris Inc.
    • 17.3.28. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL GENERIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL GENERIC DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS GENERIC DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL GENERIC DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. GENERIC DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. GENERIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. GENERIC DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL GENERIC DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL GENERIC DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL GENERIC DRUGS MARKET SIZE, BY OVER-THE-COUNTER (OTC) GENERIC DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL GENERIC DRUGS MARKET SIZE, BY OVER-THE-COUNTER (OTC) GENERIC DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL GENERIC DRUGS MARKET SIZE, BY OVER-THE-COUNTER (OTC) GENERIC DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL GENERIC DRUGS MARKET SIZE, BY OVER-THE-COUNTER (OTC) GENERIC DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL GENERIC DRUGS MARKET SIZE, BY OVER-THE-COUNTER (OTC) GENERIC DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL GENERIC DRUGS MARKET SIZE, BY OVER-THE-COUNTER (OTC) GENERIC DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL GENERIC DRUGS MARKET SIZE, BY PRESCRIPTION GENERIC DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL GENERIC DRUGS MARKET SIZE, BY PRESCRIPTION GENERIC DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL GENERIC DRUGS MARKET SIZE, BY PRESCRIPTION GENERIC DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL GENERIC DRUGS MARKET SIZE, BY PRESCRIPTION GENERIC DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL GENERIC DRUGS MARKET SIZE, BY PRESCRIPTION GENERIC DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL GENERIC DRUGS MARKET SIZE, BY PRESCRIPTION GENERIC DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANALGESICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANALGESICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANALGESICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANALGESICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANALGESICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANALGESICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANTIDEPRESSANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANTIDEPRESSANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANTIDEPRESSANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANTIDEPRESSANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANTIDIABETICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANTIDIABETICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANTIDIABETICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANTIDIABETICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANTIDIABETICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANTIDIABETICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANTIHISTAMINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANTIHISTAMINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANTIHISTAMINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANTIHISTAMINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANTIHISTAMINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANTIHISTAMINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANTIHYPERTENSIVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANTIHYPERTENSIVES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANTIHYPERTENSIVES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANTIHYPERTENSIVES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANTIHYPERTENSIVES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANTIHYPERTENSIVES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL GENERIC DRUGS MARKET SIZE, BY INHALATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL GENERIC DRUGS MARKET SIZE, BY INHALATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL GENERIC DRUGS MARKET SIZE, BY INHALATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL GENERIC DRUGS MARKET SIZE, BY INHALATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL GENERIC DRUGS MARKET SIZE, BY INHALATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL GENERIC DRUGS MARKET SIZE, BY INHALATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL GENERIC DRUGS MARKET SIZE, BY INJECTABLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL GENERIC DRUGS MARKET SIZE, BY INJECTABLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL GENERIC DRUGS MARKET SIZE, BY INJECTABLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL GENERIC DRUGS MARKET SIZE, BY INJECTABLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL GENERIC DRUGS MARKET SIZE, BY INJECTABLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL GENERIC DRUGS MARKET SIZE, BY INJECTABLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL GENERIC DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL GENERIC DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL GENERIC DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL GENERIC DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL GENERIC DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL GENERIC DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL GENERIC DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL GENERIC DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL GENERIC DRUGS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL GENERIC DRUGS MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL GENERIC DRUGS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL GENERIC DRUGS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL GENERIC DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL GENERIC DRUGS MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL GENERIC DRUGS MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL GENERIC DRUGS MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL GENERIC DRUGS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL GENERIC DRUGS MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL GENERIC DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL GENERIC DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL GENERIC DRUGS MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL GENERIC DRUGS MARKET SIZE, BY GERIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL GENERIC DRUGS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL GENERIC DRUGS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL GENERIC DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL GENERIC DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL GENERIC DRUGS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL GENERIC DRUGS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL GENERIC DRUGS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL GENERIC DRUGS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANTI-INFECTIVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANTI-INFECTIVES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANTI-INFECTIVES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANTI-INFECTIVES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANTI-INFECTIVES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANTI-INFECTIVES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL GENERIC DRUGS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL GENERIC DRUGS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL GENERIC DRUGS MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL GENERIC DRUGS MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL GENERIC DRUGS MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL GENERIC DRUGS MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL GENERIC DRUGS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM (CNS), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL GENERIC DRUGS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM (CNS), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL GENERIC DRUGS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM (CNS), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL GENERIC DRUGS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM (CNS), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL GENERIC DRUGS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM (CNS), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL GENERIC DRUGS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM (CNS), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL GENERIC DRUGS MARKET SIZE, BY DIABETES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL GENERIC DRUGS MARKET SIZE, BY DIABETES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL GENERIC DRUGS MARKET SIZE, BY DIABETES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL GENERIC DRUGS MARKET SIZE, BY DIABETES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL GENERIC DRUGS MARKET SIZE, BY DIABETES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL GENERIC DRUGS MARKET SIZE, BY DIABETES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL GENERIC DRUGS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL GENERIC DRUGS MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL GENERIC DRUGS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL GENERIC DRUGS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL GENERIC DRUGS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL GENERIC DRUGS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL GENERIC DRUGS MARKET SIZE, BY RESPIRATORY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL GENERIC DRUGS MARKET SIZE, BY RESPIRATORY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL GENERIC DRUGS MARKET SIZE, BY RESPIRATORY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL GENERIC DRUGS MARKET SIZE, BY RESPIRATORY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL GENERIC DRUGS MARKET SIZE, BY RESPIRATORY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL GENERIC DRUGS MARKET SIZE, BY RESPIRATORY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL GENERIC DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL GENERIC DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL GENERIC DRUGS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL GENERIC DRUGS MARKET SIZE, BY OFFLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL GENERIC DRUGS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL GENERIC DRUGS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL GENERIC DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL GENERIC DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL GENERIC DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL GENERIC DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL GENERIC DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL GENERIC DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL GENERIC DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL GENERIC DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL GENERIC DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL GENERIC DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL GENERIC DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL GENERIC DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL GENERIC DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL GENERIC DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL GENERIC DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL GENERIC DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL GENERIC DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL GENERIC DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL GENERIC DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL GENERIC DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. AMERICAS GENERIC DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 172. AMERICAS GENERIC DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 173. AMERICAS GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 174. AMERICAS GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 175. AMERICAS GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 176. AMERICAS GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 177. AMERICAS GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 178. AMERICAS GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 179. AMERICAS GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 183. AMERICAS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 185. AMERICAS GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 186. AMERICAS GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2025-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. NORTH AMERICA GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. NORTH AMERICA GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 192. NORTH AMERICA GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 194. NORTH AMERICA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 196. NORTH AMERICA GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 198. NORTH AMERICA GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 200. NORTH AMERICA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 202. NORTH AMERICA GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2025-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. LATIN AMERICA GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. LATIN AMERICA GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 208. LATIN AMERICA GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 210. LATIN AMERICA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 212. LATIN AMERICA GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 214. LATIN AMERICA GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 216. LATIN AMERICA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 218. LATIN AMERICA GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2025-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. MIDDLE EAST GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. MIDDLE EAST GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. MIDDLE EAST GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 256. MIDDLE EAST GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 257. MIDDLE EAST GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 258. MIDDLE EAST GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 259. MIDDLE EAST GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. MIDDLE EAST GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. MIDDLE EAST GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 262. MIDDLE EAST GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 263. MIDDLE EAST GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 264. MIDDLE EAST GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 265. MIDDLE EAST GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 266. MIDDLE EAST GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2025-2032 (USD MILLION)
  • TABLE 267. AFRICA GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 268. AFRICA GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 269. AFRICA GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 270. AFRICA GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 271. AFRICA GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 272. AFRICA GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 273. AFRICA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 274. AFRICA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 275. AFRICA GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 276. AFRICA GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 277. AFRICA GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 278. AFRICA GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 279. AFRICA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 280. AFRICA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 281. AFRICA GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 282. AFRICA GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2025-2032 (USD MILLION)
  • TABLE 283. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 286. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 287. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 288. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 289. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 290. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 291. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 292. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 293. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 294. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 295. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 296. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 297. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 298. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2025-2032 (USD MILLION)
  • TABLE 299. GLOBAL GENERIC DRUGS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 300. GLOBAL GENERIC DRUGS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 301. ASEAN GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 302. ASEAN GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 303. ASEAN GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 304. ASEAN GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 305. ASEAN GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 306. ASEAN GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 307. ASEAN GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 308. ASEAN GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 309. ASEAN GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 310. ASEAN GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 311. ASEAN GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 312. ASEAN GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 313. ASEAN GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 314. ASEAN GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 315. ASEAN GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 316. ASEAN GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2025-2032 (USD MILLION)
  • TABLE 317. GCC GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 318. GCC GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 319. GCC GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 320. GCC GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 321. GCC GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 322. GCC GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 323. GCC GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 324. GCC GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 325. GCC GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 326. GCC GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 327. GCC GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 328. GCC GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 329. GCC GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 330. GCC GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 331. GCC GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 332. GCC GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2025-2032 (USD MILLION)
  • TABLE 333. EUROPEAN UNION GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 334. EUROPEAN UNION GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 335. EUROPEAN UNION GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 336. EUROPEAN UNION GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 337. EUROPEAN UNION GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 338. EUROPEAN UNION GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 339. EUROPEAN UNION GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 340. EUROPEAN UNION GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 341. EUROPEAN UNION GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 342. EUROPEAN UNION GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 343. EUROPEAN UNION GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 344. EUROPEAN UNION GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 345. EUROPEAN UNION GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 346. EUROPEAN UNION GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 347. EUROPEAN UNION GENERIC DRUGS MA